Shenzhen Kangzhe Biotechnology Co., Ltd.
Clinical trials sponsored by Shenzhen Kangzhe Biotechnology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill CMS-D017 enters first human safety trials Results expected Nov 2026 (estimated)
- Radioactive tracer tracks an experimental Drug's journey through the body Results expected Dec 2026 (estimated)
- New pill could ease heavy periods from fibroids Results expected Jan 2027 (estimated)
-
New pill could ease heavy periods from fibroids
Disease control Recruiting nowThis study tests a new drug called CMS-D002 for women with uterine fibroids who have heavy menstrual bleeding. About 120 women aged 18-50 will take either the drug or a placebo daily for 12 weeks. The goal is to see if the drug can reduce bleeding to normal levels and shrink fibr…
Phase 2 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill CMS-D017 enters first human safety trials
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare conditions: paroxysmal nocturnal hemoglobinuria (a blood disorder) and complement-mediated kidney disease. Par…
Phase 1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC